MINI FUTURE LONG - ELI LILLY & CO | Market Closed - Euronext Paris 10:00:02 28/06/2024 pm IST | ||
| 7.288 EUR | +1.59% |
|
| Current month | +32.70% | ||
| 1 month | +37.79% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 28/24/28 | 7.325 | +2.10% |
| 27/24/27 | 7.174 | -0.75% |
| 26/24/26 | 7.228 | +1.09% |
| 25/24/25 | 7.15 | +0.55% |
| 24/24/24 | 7.111 | +3.36% |
Real-time Euronext Paris
Last update June 28, 2024 at 10:00 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| OO5NB | |
| ISIN | NLBNPNL2OUQ5 |
| Date issued | 15/03/2024 |
| Strike | 520 $ |
| Maturity | Unlimited |
| Parity | 50 : 1 |
| Emission price | 4.58 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.449 € |
|---|---|
| Lowest since issue | 3.87 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
905.4
USD
Average target price
868.9
USD
Spread / Average Target
-4.03%
- Stock Market
- Certificates
- OO5NB Certificat
